GlassScriptPhysician profile
Jeffery A Sklar
NPI 1104898204
$8,436.19
in general payments reported to CMS, 2019-2025
40 companies · $1,394 in 2025
The $1,394 reported for 2025 was more than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,920 · 2020: $301 · 2021: $1,072 · 2022: $1,264 · 2023: $1,347 · 2024: $1,139 · 2025: $1,394.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,849 · Education: $30.54.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,849.32 |
| Education | $30.54 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merz North America, INC. | $1,222.25 | 2019-2023 | Xeomin |
| Janssen Biotech, INC. | $1,004.17 | 2019-2025 | Tremfya, Simponi Aria, Simponi |
| Sun Pharmaceutical Industries INC. | $641.68 | 2019-2025 | Winlevi, Absorica Ld, Odomzo |
| Arcutis Biotherapeutics, INC. | $597.59 | 2024-2025 | Zoryve |
| Regeneron Healthcare Solutions, INC. | $473.35 | 2019-2025 | Dupixent |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $445.41 | 2019-2025 | Siliq, Duobrii, Arazlo |
| Genzyme Corporation | $444.79 | 2019-2025 | |
| Abbvie INC. | $423.36 | 2019-2025 | Botox, Skyrizi |
| Galderma Laboratories, L.P. | $361.82 | 2019-2025 | Nemluvio, Aklief, Epsolay |
| Pfizer INC. | $326.97 | 2019-2024 | |
| Novartis Pharmaceuticals Corporation | $317.78 | 2019-2025 | |
| Incyte Corporation | $269.07 | 2021-2025 | Opzelura |
| Almirall LLC | $262.74 | 2019-2025 | Klisyri |
| Amgen INC. | $244.19 | 2020-2025 | Otezla, Otezla |
| Mayne Pharma Commercial LLC | $193.46 | 2019-2023 |
Show all 38 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biofrontera INC. | $180.00 | 2019-2022 | |
| Epi Health, LLC | $160.95 | 2019-2022 | |
| Leo Pharma INC. | $153.22 | 2019-2022 | |
| Lilly USA, LLC | $111.76 | 2019-2025 | Taltz, Ebglyss |
| Allergan, INC. | $88.13 | 2019-2022 | |
| Genentech USA, INC. | $51.21 | 2019-2024 | Actemra, Erivedge |
| Celgene Corporation | $47.55 | 2019 | |
| Paratek Pharmaceuticals, INC. | $41.89 | 2021 | |
| Vyne Pharmaceuticals INC. | $38.07 | 2021 | |
| Encore Dermatology INC. | $35.99 | 2019 | |
| Dermavant Sciences, INC. | $35.16 | 2024 | Vtama |
| Merck Sharp & Dohme LLC | $34.49 | 2019 | |
| Dermira, INC. | $29.36 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $27.36 | 2022 | |
| Mylan Pharmaceuticals INC. | $24.77 | 2019 | |
| Lnhc, INC | $24.42 | 2025 | Zelsuvmi |
| Cipher Pharmaceuticals US LLC | $23.62 | 2025 | Spinosad, Natroba |
| Dusa Pharmaceuticals, INC. | $22.69 | 2019 | |
| Botanix Sb INC | $21.64 | 2025 | Sofdra |
| Stemline Therapeutics INC. | $17.85 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $13.34 | 2023 | Sotyktu |
| Mission Pharmacal Company | $12.27 | 2020 | |
| Strata Skin Sciences, INC. | $11.82 | 2019 |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jeffery Sklar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.